Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

MSD’s Keytruda® Sales for Q3/24 Reach US $7.4B

Oct 31, 2024

On 31 October 2024, Merck, known as MSD outside the US and Canada, published its Q3 2024 financial results, including 17% growth (21% excluding foreign exchange impact) in Keytruda® (pembrolizumab) sales, to US $7.4 billion.  This growth is attributed to increased global uptake in earlier-stage indications of Keytruda®, including triple-negative breast cancer, renal cell carcinoma and non-small cell lunch cancer (NSCLC), together with continued global demand for metastatic indications.

The increased global uptake of Keytruda® is reported to have helped drive MSD’s total global sales for Q3 2024 to US$16.7 billion, an increase of 4% year on year.

Recent regulatory milestones for Keytruda® include: the FDA approval in September 2024 of Keytruda® plus pemetrexed and platinum chemotherapy as first-line treatment for unresectable advanced or metastatic malignant pleural mesothelioma; approvals in Europe for Keytruda® plus Padcev® as first-line treatment of unresectable or metastatic urothelial carcinoma (September 2024) and two gynaecological cancers (October 2024, marking the 30th EU approval); and approvals in Japan for certain patients with NSCLC and for radically unresectable urothelial carcinoma (September 2024).